ArticleThe mental health clinician2026
Pharmacists expand access to contingency management in patients with substance use disorders.
Article in The mental health clinician, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Contingency management (CM) is a behavioral intervention that offers incentives to individuals who meet their goals in a substance use disorder (SUD) treatment program. This review highlights CM for abstinence, which is related to abstaining from using a target substance, and CM for adherence, which is related to adherence to receiving injectable medications for SUD. Clinical pharmacist practitioners (CPPs) are well-suited to serve as resources for the growth of CM. Practice Description: Standardized protocols for CM are used across the Department of Veterans Affairs (VA) healthcare facilities involving various interprofessional team members. All patients receiving CM for abstinence or CM for adherence to injectable medications for SUD involving a CPP at 3 VA facilities from November 13, 2017, to December 31, 2023, were retrospectively reviewed to describe patient characteristics and key outcomes. Patients receiving CM for adherence to injectable medications (n = 98) completed 88.3% of appointments on time, with a total of 574 injections of either naltrexone extended-release injection (XR) or buprenorphine XR given. Patients enrolled in CM for abstinence (n = 51) provided 566 total urine samples within the study period, 80% of which were negative for the targeted substance. Conclusion: CPPs are expanding access to CM for abstinence and adherence to injectable medications for SUD, with similar rates of abstinence and adherence seen in the current literature. Continued expansion of the CPP provision of CM in various outpatient settings would further expand access to these evidence-based treatments for patients with SUD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.